title: Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland.
abstract: OBJECTIVE
  Until recently, surgery was the only remaining choice for moderate to severe chronic ulcerative colitis patients who failed standard treatment or when it was not tolerated. Anti-TNFα treatment is a new, non-invasive option for the management of ulcerative colitis. The objective of this study was to assess the cost-effectiveness of induction and maintenance treatment up to 1 year of ulcerative colitis with adalimumab/standard care and standard care alone in Poland.
  
  
  METHODS
  A Markov model was used to estimate the expected costs and effects of adalimumab/standard care and a standard care alone. For each treatment option, the costs and quality adjusted life years were calculated to estimate the incremental cost-utility ratio. The analysis was performed from the perspective of the Polish public payer and society over a 30-year time horizon. Different direct and indirect costs and utility values were assigned to the various model health states.
  
  
  RESULTS
  The treatment of ulcerative colitis patients with adalimumab/standard care up to 1 year instead of a standard care alone resulted in 0.14 additional years of life with full health (QALYs). The incremental cost-utility ratio of adalimumab/standard care compared to the standard care alone is estimated to be 76,120 €/QALY gained from NHF perspective and 71,457 €/QALY gained from social perspective.
  
  
  CONCLUSIONS
  The biologic treatment of ulcerative colitis patients with adalimumab/standard care is more effective but also more costly compared with standard care alone.
authors: StatSoft Polska Sp. z o.o., Krakow, Poland.
authors: Ewa
authors: E
authors: Stawowczyk
authors: Department of Drug Management, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, 20, Grzegórzecka street, 31-531, Kraków, Poland. pawel.kawalec@uj.edu.pl.
authors: Paweł
authors: P
authors: Kawalec
authors: Department of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland.
authors: Andrzej
authors: A
authors: Pilc
mesh_terms: D000068879:Adalimumab / Q000191:economics* / Q000627:therapeutic use; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000191:economics* / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008297:Male; D008390:Markov Chains; D018803:Models, Economic; D011044:Poland; D019057:Quality-Adjusted Life Years
chemical_list: D000893:Anti-Inflammatory Agents; D000068879:Adalimumab
keywords: Adalimumab; Cost-utility; Economic analysis; Indirect costs; Ulcerative colitis